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bsessive-compulsive disorder (OCD) is char-
acterized by obsessions and compulsions, but it has
become clear that there are a significant number of other
disorders that have core obsessive and compulsive fea-
tures.Disorders that include such features cross several
diagnostic categories and can be grouped according to
the focus of the symptoms:bodily preoccupation,impulse
control,or neurological disorders (Table I).In addition
to having obsessive and compulsive symptoms, all of
these disorders also have some similarities in patient
characteristics, course, comorbidities, neurobiology, or
treatment response.Thus,an obsessive-compulsive (OC)
spectrum has been proposed,for which all of these dis-
orders are candidates.
1-4 Each of these disorders can often
be chronic and devastating in terms of the suffering
caused, the interference with functioning in important
areas of life, and the economic toll to individuals and
society.
Individuals with these disorders exhibit repetitive behav-
iors because they have a defect in the mechanism that
enables them to inhibit acting.
2The disorders vary in the
extent to which they are characterized by compulsivity
versus impulsivity,and this difference is often discussed in
terms of a compulsive-impulsive spectrum.
2-4They vary in
numerous ways beginning with the phenomenology of
this inability to resist acting.Compulsive disorders include
OCD,body dysmorphic disorder (BDD),hypochondria-
sis, and anorexia nervosa. Individuals who act compul-
sively are avoiding risk and seeking safety;these individ-
uals appear to have an exaggerated sense of harm and are
driven to avoid harm or reduce anxiety and distress by
performing the compulsive behaviors.The impulsive dis-
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O
The obsessive-compulsive spectrum is an important con-
cept referring to a number of disorders drawn from sev-
eral diagnostic categories that share core obsessive-com-
pulsive features. These disorders can be grouped by the
focus of their symptoms: bodily preoccupation, impulse
control, or neurological disorders. Although the disorders
are clearly distinct from one another, they have intriguing
similarities in phenomenology, etiology, pathophysiology,
patient characteristics, and treatment response. In com-
bination with the knowledge gained through many years
of research on obsessive-compulsive disorder (OCD), the
concept of a spectrum has generated much fruitful
research on the spectrum disorders. It has become appar-
ent that these disorders can also be viewed as being on a
continuum of compulsivity to impulsivity, characterized by
harm avoidance at the compulsive end and risk seeking at
the impulsive end. The compulsive and impulsive disorders
differ in systematic ways that are just beginning to be
understood. Here, we review these concepts and several
representative obsessive-compulsive spectrum disorders
including both compulsive and impulsive disorders, as well
as the three different symptom clusters: OCD, body dys-
morphic disorder, pathological gambling, sexual compul-
sivity, and autism spectrum disorders. 
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and sexual compulsivity (SC).Those who act impulsively
are risk takers,who underestimate the likelihood or sever-
ity of possible harm;they are seeking pleasure,arousal,or
gratification;their actions may also be aggressive and are
often accompanied by feelings of loss of control. The
impulsive disorders are also often discussed as addictions,
and treatment programs modeled after those used for
substance abuse have arisen to treat them.These disor-
ders have many similarities to addictions,but differ from
traditional addictions in numerous ways,most notably in
that they do not involve the intake of psychoactive sub-
stances.They are also sometimes considered as compul-
sive disorders,but are differentiated from compulsive dis-
orders in our conceptualization for several reasons.For
example,at least in the initial stages of the disorder,the
repetitive behaviors are sought for pleasure and they
involve risk taking rather than risk avoidance.The seem-
ingly opposing drives of compulsivity and impulsivity can
exist at the same time in one individual or appear at dif-
ferent times during the course of a disorder.
Baxter and his colleagues have suggested that OC spec-
trum disorders as a whole may involve corticostriatal dys-
function with the specific disorders having different areas
of dysfunction within this system.
5,6 Structural imaging
supports this hypothesis;studies have shown volumetric
abnormalities in these structures in numerous OC spec-
trum disorders.
6 In addition, the different ends of the
compulsive-impulsive spectrum seem to differ systemat-
ically in their pathophysiology and thus differ somewhat
in their treatment response.
2,7 Indications are that com-
pulsive disorders are characterized by increased frontal
lobe activity and increased sensitivity of specific sero-
tonin receptor subsystems,while impulsive disorders are
characterized by decreased frontal lobe activity and
decreased presynaptic serotonergic function.
2
We will first outline the characteristics of OCD,the pro-
totypical OC spectrum disorder, and then compare it
with several OC spectrum disorders drawn from differ-
ent symptom categories and from different ends of the
compulsive-impulsive spectrum.
Obsessive-compulsive disorder
OCD is characterized by obsessions and compulsions.
The obsessions are recurrent thoughts, impulses, or
images, which are intrusive and ego dystonic; they are
related to basic fears or urges that are distressing to the
individual,such as contamination,aggression,sex,reli-
gion/scrupulosity,order/symmetry,hoarding,or patho-
logical doubt.The compulsions are repetitive behaviors,
including mental acts that the individual feels compelled
to perform to reduce the anxiety created by the obses-
sions.The compulsions are often performed in specific
ways,and can result in elaborate rituals.
With the exception of children, individuals with OCD
recognize at some point in time that their obsessions are
excessive or unreasonable.This insight can vary over time
and from situation to situation.It is not unusual for an
individual to have insight when not in an OCD-provok-
ing situation,but to have insight disappear when faced
with an OCD fear and thus feel compelled to perform a
ritual.
The obsessions and compulsions are intrusive,preoccu-
pying, and distressing. The obsessions interfere with
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Selected abbreviations and acronyms
ASD autism spectrum disorder
BDD body dysmorphic disorder
CBT cognitive behavioral therapy
OCD obsessive-compulsive disorder 
OC obsessive-compulsive (spectrum)
PG pathological gambling
PRD paraphilia-related disorder
SC sexual compulsivity
SNRI serotonin and norepinephrine reuptake inhibitor 
SRI serotonin reuptake inhibitor
SSRI selective serotonin reuptake inhibitor
Table I. Obsessive-compulsive disorders.
Category Representative disorders
Bodily preoccupation Body dysmorphic disorder (BDD)
Hypochondriasis
Eating disorders
Depersonalization disorder
Impulse control Pathological gambling (PG)
Sexual compulsivity (SC)
Kleptomania
Trichotillomania
Intermittent explosive disorder
Borderline personality disorder
Antisocial personality disorder
Neurological disorders Autism
Asperger disorder
Tourette syndrome
Sydenham choreaattention and concentration,thus interfering with cogni-
tive tasks and often social interactions.The obsessions
and compulsions can be very time-consuming:they inter-
fere with functioning because of the time they occupy,
and because patients with OCD often develop patterns
of avoidance of situations or things that provoke their
obsessions or compulsions.
OCD typically begins in late adolescence or early 
adulthood with an earlier age of onset for males than
females.
8-10 In adult clinical samples, OCD is equally
common in females as in males,
11 but, due to a higher
incidence of childhood-onset OCD in males, younger
samples have more males than females.
12 Compared
with clinical samples, epidemiological studies tend to
show a later age of onset and a higher proportion of
females than males.
12
The lifetime prevalence of OCD is estimated to be
between 1.9% and 3.3%.
12 Most studies show a chronic
course that extends across the lifetime with waxing and
waning of symptoms, although in about 10% of cases
there is a malignant deteriorating course.
9,13
Neurobiological evidence shows clearly that the serotonin
system is important in OCD.This evidence has come from
treatment response to serotonin reuptake inhibitors
(SRIs), including studies of SRIs versus desipramine,
which demonstrated the selective efficacy of SRIs,
14,15 as
well as from pharmacological challenge studies and cere-
brospinal fluid neurotransmitter metabolite studies.
16
There is also evidence,however,of a role for the dopamine
system in OCD on the basis of both theory (derived from
basic human and animal research) and the efficacy of
dopaminergic augmentation in refractory OCD.
16,17
Neuroimaging in OCD has revealed much about the dis-
order and about the effects of treatment.Structural imag-
ing supports the hypothesis that the OC spectrum disor-
ders involve corticostriatal dysfunction
6; specifically,
magnetic resonance imaging (MRI) studies have shown
volumetric abnormalities in the caudate and a rightward
shift in caudate volume.Functional imaging in OCD has
shown increased activity in the corticostriatal pathway
involving the orbitofrontal cortex and the caudate
nucleus.
6,18 Importantly,successful treatment of OCD with
either SRI or cognitive behavioral therapy (CBT) results
in normalization of orbitofrontal activity.
6,19,20
There are now a number of pharmacotherapies available
for treating OCD.The first medication discovered to be
effective in OCD was clomipramine,a serotonin and nor-
epinephrine reuptake inhibitor (SNRI).
21The develop-
ment of selective serotonin reuptake inhibitors (SSRIs)
greatly expanded the options for treatment of OCD.The
SSRIs have more favorable side-effect profiles than
clomipramine,and have become the first-line treatments
for OCD.They include citalopram,escitalopram,fluoxe-
tine,fluvoxamine,paroxetine,and sertraline.Venlafaxine,
a newer SNRI,is also used to treat OCD.Most have been
established as effective in OCD through large controlled
trials:citalopram,
22 clomipramine,
23 fluoxetine,
24,25 fluvox-
amine,
26,27 paroxetine,
28 and sertraline.
29,30 In addition,
there is evidence for the efficacy of venlafaxine in treat-
ment-resistant OCD.
31The SRIs (including all the SSRIs
and the SNRIs clomipramine and venlafaxine) are gen-
erally used in higher doses for OCD than for depression
and may require an extended period of time, 8 to 12
weeks or longer,before they ameliorate symptoms to a
clinically significant degree.Two reasonably large stud-
ies report rates of response to SRI treatment for SRI-
naive patients;these rates were about 53%
32 and 42%.
33
From 60% to 80% of patients with OCD respond to mul-
tiple trials of SRIs,
34-38 with most studies reporting nonre-
sponder rates closer to 60%. No SRI has been proven
more effective than others in head-to-head comparisons,
so the selection of an SRI for individual patients with
OCD can be made on the basis of side effects and half-
life.The efficacy seems to be maintained over time with
continuing SRI treatment,
28,39,40 but since OCD symptoms
generally worsen during stress, some fluctuations in
symptom severity while taking medication are not
unusual;symptoms recur when treatment is ended.
28,39-41
Unfortunately,even with a typical 30% to 60% decrease
in their OCD symptom severity,
42 many patients are left
with significant symptoms.Because of this,other pharma-
cological strategies have been used.Most commonly,neu-
roleptics or agents with serotonergic properties are used
to augment SRI treatment. Of the neuroleptics, only
risperidone has been established in controlled trials as an
effective augmentation of SRIs in treatment-resistant
OCD.
43,44Additionally,several open-label trials have found
olanzapine an effective augmentation of SRIs in OCD.
45-
49 Subgroups of OCD patients may be particularly helped
by neuroleptic augmentation;most definitively,patients
with OCD and comorbid tics have responded well to this
strategy,
17 which supports the position that the dopamin-
ergic system plays a role in some subtypes of OCD.
Haloperidol was found to be an effective augmentation to
fluvoxamine in a placebo-controlled trial in patients with
comorbid OCD and tics, but not in those with OCD
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50 Similarly,there is some evidence that patients with
schizotypal personality disorder may do better with neu-
roleptic augmentation.An open-label trial of pimozide was
effective in treating the OCD symptoms in patients with
either comorbid tics or schizotypal personality.
51
Among the serotonergic agents reported in the literature
as useful augmentations to SRIs in OCD are buspirone,
lithium,trazodone,clonazepam,and clomipramine (aug-
menting an SSRI).Buspirone and lithium were reported
to be helpful in OCD on the basis of open-label trials and
case series, but controlled trials have produced disap-
pointing results
21,52There has been no controlled trial of
trazodone augmentation. Small controlled trials have
provided promising results for augmentation with clon-
azepam
42 and clomipramine.
53
One other pharmacotherapy,pindolol,has been proven
to be effective as an SRI augmentation agent in a small
controlled study.
54
The only proven psychological treatment for OCD is
CBT;exposure and response prevention is the most estab-
lished specific therapeutic technique and has been
endorsed as the treatment of choice by the Expert
Consensus Panel for Obsessive-Compulsive Disorder.
55
The first report of successful behavioral treatment of
OCD was by Meyer in 1966
56;since then numerous trials
have been conducted to support its efficacy.Several meta-
analyses of CBT trials have concluded that OCD symp-
toms improved significantly with CBT treatment.
57-61
Body dysmorphic disorder
BDD or “imagined ugliness”is a disorder of body image
in which a person is preoccupied and distressed by an
appearance defect that is either imagined or,if there is a
slight anomaly,their distress is markedly excessive com-
pared with the anomaly itself.
62The symptom dynamics are
similar to OCD in that individuals suffering from BDD
have obsessive thoughts or images that create distress,and
they perform compulsive behaviors in an attempt to
reduce the distress.In BDD,the obsessive thoughts focus
on their imagined defect (eg,a horribly ugly face,nose,or
other body part),what it means for their life (eg,rejection,
humiliation,or social and occupational failure),and how
they can solve the physical problem (eg,cosmetic surgery,
dermatological or other treatments,or camouflage).The
compulsive behaviors include checking their appearance
(eg,looking in mirrors or asking others for reassurance),
temporary solutions (eg,camouflaging with makeup,cloth-
ing,or accessories),or the search for permanent solutions
(searching the Internet for new procedures,shopping for
new creams or appliances,or consulting experts).They also
compulsively scrutinize the appearance of others,particu-
larly focusing on the feature(s) they dislike in themselves;
this comparison, usually increases their distress at how
badly they look,leading one patient to refer to it as “com-
pare and despair.”As with OCD,avoidance is prominent;
BDD patients typically avoid social situations and situa-
tions in which they believe their disliked feature is partic-
ularly noticeable.
Like OCD, BDD is on the compulsive, harm-avoidant
end of the compulsive-impulsive spectrum;patients are
driven to prevent the social rejection and humiliation
that they feel is inevitable due to their flawed appear-
ance.Aside from the different obsessional focus,BDD
differs from OCD in several other significant ways.BDD
rituals tend to be less effective at reducing distress than
OCD rituals.BDD is also characterized by poorer insight
than OCD.
63As noted earlier,most OCD patients real-
ize,at least when not in an OCD moment,that their rit-
uals make no sense; in contrast, many BDD patients
believe that they really are ugly,abnormal,or even mon-
strous, and that their ritual behaviors not only make
sense, but are also essential. Poor insight in BDD is a
major deterrent to psychiatric and psychological treat-
ment;most BDD patients present to cosmetic surgeons,
dermatologists, dentists, or others who they think can
resolve the appearance problem.They can be frustrated
and angered by referral for mental health treatment
because they see their appearance as the problem and
fixing their appearance as the only solution.
There have been no epidemiological studies of BDD and
so clear prevalence rates are not available;however,it has
been estimated that as many as approximately 2% of non-
clinical samples
64,65 and 12% of psychiatric outpatients
66 suf-
fer from BDD. Like OCD, in clinical samples BDD
appears to be equally prevalent among males and
females.
67 It also has a chronic lifelong course with some
waxing and waning of symptoms, including worsening
under stress,but the majority of patients with BDD report
a generally deteriorating course,rather than a steady or
improving one.
68 BDD has a somewhat earlier age of onset
than OCD with the average age of onset being in adoles-
cence at 16 to 17 years of age.
67,68 In BDD,the focus of con-
cern can change from one body part to another over time.
Work on the pathophysiology of BDD is just beginning.
Recently,the first imaging study in BDD reported a shift
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matter volume.
69These findings are consistent with the
hypothesis that BDD is an OC spectrum disorder.
Like OCD,BDD has been shown to respond to SRIs and
rarely to other pharmacological monotherapy.Two con-
trolled SRI trials have been performed,one comparing
clomipramine with desipramine,
70 thus establishing the
selective efficacy of an SRI, and the second comparing
fluoxetine with placebo,
71 further supporting the efficacy
of SRIs.In practice,pharmacotherapy for BDD generally
follows the same guidelines as for OCD,in terms of the
agents used, dosages, and latency and maintenance of
response.This similarity to OCD is supported by the two
controlled trials,open-label trials,case series,and retro-
spective studies.
72-75 Since there are more cases with poor
insight and perhaps more refractory cases, use of aug-
mentation strategies may be more frequent.One differ-
ence from OCD is that pimozide seems to be ineffective
in BDD on the basis of a double-blind,placebo-controlled
trial of pimozide as an augmentation of fluoxetine (K.A.
Phillips,personal communication).This is somewhat sur-
prising since it is not only effective in some cases of OCD
(albeit those with comorbid tics or schizotypal personal-
ity disorder),but also because it is effective in parasitosis,
which was included along with BDD in the earlier diag-
nostic category monosymptomatic hypochondriasis.
76,77A
common difficulty in pharmacotherapy for BDD is that
appearance-altering side effects must be kept in mind;
patients with hair or skin concerns,for example,will be
unlikely to accept a medication or be compliant with it if
hair loss or skin problems are possible side effects.
Like OCD,BDD also seems to respond to CBT,particu-
larly exposure and response prevention, rather than
other psychotherapeutic interventions.A number of stud-
ies and case reports of group
78,79 and individual
80-82 treat-
ment with CBT have shown promising results. Poor
insight presents a challenge in terms of engaging patients
in therapy,but does not preclude successful treatment.
Indeed, correction of the misperception about their
appearance does not seem to be necessary for successful
treatment or to add to treatment success.
83
Pathological gambling
PG is a disorder of impulse control characterized by
recurrent gambling behavior that is maladaptive (ie,loss
of judgment or excessive gambling) and in which per-
sonal,family,and/or vocational endeavors are disrupted.
62
PG shares many characteristics with other impulse con-
trol disorders such as kleptomania and pyromania in that
individuals with these disorders have the irresistible
impulse to perform harmful acts, have loss of control,
may harm self or others,and engage in risky behavior.
They share a pre-act arousal and/or tension,and the per-
formance of the act results in relief or gratification,some-
times followed by guilt.PG is characterized by an inabil-
ity to resist the urge to gamble and is often progressive.
Patients may show “tolerance”and thus need to gamble
with increasing amounts of money.
The course of PG tends to be chronic,although the pat-
tern of gambling may be regular or episodic.During peri-
ods of gambling,the individuals often have hours of daily
preoccupation with gambling,including planning future
gambling,reliving past gambling experiences,and figur-
ing out how to obtain money for gambling.They may lie
and defraud people to finance their gambling.Individuals
with PG commonly experience tormenting and devas-
tating distress over their gambling behavior.Chronicity
is often associated with increases in frequency and
amount gambled; additionally, gambling may increase
during periods of heightened stress.Gambling thus leads
to more and more severe consequences,and more gam-
bling,and may spiral out of control.Thus,the combina-
tion of illness chronicity,severe interference with normal
life activities,and unavailability of treatment frequently
leads to severe personal, familial, financial, social, and
occupational impairment.
In 1998,86% of adults in the USA were estimated to have
participated in some type of gambling over their lifetime,
up from 63% in 1975;the past-year figures increased only
slightly,from 61% to 68%.
84The past-year prevalence of
PG among adults has been estimated to be between 0.9%
and 2.0%, while the lifetime adult prevalence has been
estimated to be between 1.5% and 2.3%.
85The prevalence
rates are higher among adolescents and college students.
As with OCD,demographic factors in treatment-seeking
populations differ from those in epidemiological/general
population surveys.Treatment-seeking PG patients are
more likely than those identified by survey to be male
(93% versus 64%), to be over 30 years old (82% versus
62%),and to be Caucasian (91% versus 57%).
86 Reported
lifetime gambling increased for both males and females
from 1975 to 1998;however,the increase was much larger
for women,from 61% to 83%,than for men,from 75% to
88%,resulting in a decrease in the sex difference in gam-
bling.
84 Yet, past-year gambling remains unchanged for
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women from 55% to 60%, resulting in only a slight
decrease in the sex difference.
84 Legalized gambling has led
to more gambling opportunities and new forms
87; the
explosion seems likely to account for the decrease in the
sex difference in social gambling,yet the sex difference in
PG has remained.This sex difference in PG, with males
predominating in both clinical and population samples,is
in contrast to the sex parity often found in OCD and BDD.
Gender differences have also been reported in the onset
and course of PG.In males,PG usually begins in adoles-
cence
88-90 or young adulthood,
90 and may remain undiag-
nosed for years.When male PG patients are first diag-
nosed,they often present with a 20- to 30-year gambling
history,with gradual development of PG.In some cases,
PG suddenly occurs in male social gamblers following a
significant loss,stressor,or increased exposure.
91 In con-
trast,PG in females is more likely to occur later in life and
delay in seeking treatment is approximately 3 years.Thus,
as a result of the differences in onset and duration,female
PG patients generally have a better prognosis than male
PG patients.
91 Male and female gamblers differ in the
types of gambling they prefer,with men more likely to bet
on sporting events,cards,and at the track,while women
prefer slot machines and bingo.
90 It is unknown whether
males and females with PG represent truly different sub-
groups with differences in pathophysiology and treatment
response.
We recently completed an FDG (fluorodeoxyglucose)
positron emission tomography (PET) study in PG.The
scans were acquired while the patients were engaged in a
computerized gambling task either for a monetary reward
or for computer points only. Gambling for monetary
reward blackjack was associated with significantly higher
relative metabolic rate in the primary visual cortex,the cin-
gulate gyrus,the putamen,and prefrontal areas.We would
expect normal subjects to show activation in both mone-
tary and pure gambling conditions,but a study including
both PG and social gamblers has not yet been done. In
addition to demonstrating that the unique aspects of mon-
etary reward compared with pure gambling are reflected
in the activation patterns similarly to past imaging studies
of reward strategy planning,
92 the results are generally con-
sistent with symptom-provocation studies in OCD.
A possible selective efficacy of SRIs has been demon-
strated in PG.Our studies have assessed the efficacy and
tolerability of the SSRI fluvoxamine in PG without
comorbidities.In small single-blind
93 and double-blind
94
trials,we found that fluvoxamine reduced gambling urges
and behavior.Other recently published studies further
establish the efficacy of SRIs in the treatment of PG.
These include a small open-label citalopram trial
95 and
a larger double-blind, placebo-controlled paroxetine
trial.
96 Compared with OCD,the treatment response to
SRIs is evident earlier and at lower doses.In addition,in
an open-label trial,the serotonin antagonist nefazodone
has been found to be effective in PG.
97
PG seems to respond to a wider range of monotherapies
than OCD;notably,there are case reports
98,99 and a single-
blind study
100 suggesting that mood stabilizers are effective
in PG.We recently completed a double-blind,placebo-con-
trolled study of sustained-release lithium in PG patients
with comorbid bipolar disorder. Lithium significantly
improved both impulsive gambling and affective instabil-
ity compared with placebo in this population.In addition,
the opiate antagonist naltrexone may beneficial in PG.
101
Just as PG responds to a wider range of pharmacological
agents than does OCD, PG also responds to more psy-
chotherapeutic modalities.Many treatment interventions
for PG are similar to those for substance abuse disorders
rather than OCD, and were created on the basis of the
addiction model.The interventions reported in the liter-
ature for PG are self-help groups,inpatient treatment pro-
grams,and motivational interviewing (MI) approaches,as
well as CBT.
Self-help groups such as Gamblers Anonymous (GA),
which is structurally similar to Alcoholics Anonymous
(AA),are widely available,but their efficacy is limited;
only 8% of GA members reported total abstinence at a
1-year follow-up and 7% at a 2-year follow-up.
102
Inpatient treatment and rehabilitation programs for PG,
also based on programs for substance abuse,emerged in
the early 1970s.
103,104 Outcome studies show that approxi-
mately 55% of patients report abstinence at 1-year fol-
low-up.
105,106 MI, which has been successful in treating
alcohol use disorders,has recently been applied to PG
with promising preliminary results.
107
Behavioral and cognitive approaches have been used to
treat PG. Aversive therapy was the most commonly
employed early method
108 with published studies primar-
ily based on small sample,uncontrolled studies of in vivo
aversive therapy technique (eg, electric shocks).
109-112
Imaginal desensitization was found to be more effective
than three other behavioral techniques (aversion therapy,
imaginal relaxation,and in vivo exposure) in a sample of
120 patients.
113 CBT involving exposure and response pre-
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vention—the technique used effectively for OCD—was
found to substantially decrease gambling urges as
reported in two case studies of PG.
114 It is known that
gamblers make a number of cognitive errors that play a
role in maintaining their disorder,and cognitive therapy
aimed at correcting these errors and misperceptions has
shown promise.
115,116 Thus, cognitive therapy may have
potential for the treatment of PG either alone or,more
likely, as part of a comprehensive treatment program;
however,further structured and controlled investigations
and long-term outcome studies are needed.
Sexual compulsivity
There are two general categories of SC.One category con-
sists of paraphilias,which are recurrent sexual fantasies,
urges,or behavior that involves nonhuman objects,the suf-
fering or humiliation of oneself or one’s partner,or chil-
dren or other nonconsenting persons.They cause clinically
significant distress or interfere with functioning in inter-
personal and other areas.
62 Paraphilias include exhibition-
ism,fetishism,frotteurism,pedophilia,sexual masochism
and sadism,and voyeurism,some of which have serious
legal consequences.The second category of SC,referred to
as paraphilia-related disorders (PRDs) and sometimes as
sexual addiction,consists of individuals who engage in nor-
mative sexual arousal and behaviors,that is,masturbation
and/or sexual behaviors that are typical in heterosexual or
homosexual relationships,but carry out these behaviors at
a frequency or intensity that creates problems in relation-
ships or other areas of functioning.PRDs are not specified
as disorders in the Diagnostic and Statistical Manual of
Mental Health,Fourth Edition,Text Revision (DSM-IV),
62
but can be diagnosed as a paraphilia not otherwise speci-
fied.Initially,the sexual behaviors of both the paraphilias
and the PRD are usually pleasure producing;however,at
least when the sexual compulsion is severe,it is clear that
they are compulsive-repetitive behaviors.Individuals who
have sexual compulsions often feel their behavior is out of
control and the sexual activities themselves and the
amount of time spent searching out or planning them can
become extremely distressing and disruptive.
Sexual compulsions are distinct from the sexual obses-
sions commonly found in OCD. Sexual obsessions in
OCD consist of sexual thoughts and images that are expe-
rienced as intrusive,ego dystonic,and morally repugnant.
Ordinarily,these obsessions do not lead to carrying out
the sexual acts and the individuals engage in ritual behav-
iors to prevent themselves from actually carrying out the
sexual behavior or to “undo”their thoughts or potential
behaviors.Although individuals with PRD may feel guilt
or disgust at their behavior,they do carry out these behav-
iors and,at least initially,find them pleasurable.
Like PG,SC is on the impulsive side of the compulsive-
impulsive spectrum;the behaviors can be considered risk
seeking and,at least at the time of the activity,can be char-
acterized by an underestimation of the negative conse-
quences and an inability to control the behavior.This is the
key to the increased risk of human immunodeficiency
virus (HIV) among this population.Phenomenologically,
as is characteristic of impulsive disorders,the repetitive
sexual behavior has pleasurable aspects; however, over
time,pleasure seems to be outweighed by distress.
Good epidemiological data are not available since sexual
disorders have not been included in the major population
studies conducted;indeed,it is difficult to see how these
disorders could have been covered adequately since the
likelihood of obtaining honest replies seems minimal.
Estimates of the prevalence of SC range from 3% to
6%.
117 Paraphiliac sexual behaviors are thought to begin
in childhood, adolescence, or early adulthood,
118 and
PRDs are thought to begin around age 18 on average.
119,120
SC tends to be cyclical,but there is generally a worsening
trend with the sexual activities becoming more extreme
and functioning becoming more disrupted over time.
121 SC
is three times more common in males than females.
122,123
This is a more extreme preponderance of males than
found in PG,which is in contrast to the gender neutrality
often found in clinical OCD and BDD samples.
Research on the pharmacotherapy of SC is limited, to
date only case reports and small,non–placebo-controlled
studies have been published,although we are currently
conducting a placebo-controlled trial of citalopram in
narcissistic personality disorder.As was found for OCD,
there is evidence that SRIs are beneficial in SC.This is
probably due in part to the side effect of decreasing
libido, but it seems that SRIs also work by reducing
obsessive thoughts and behaviors more directly.Their
efficacy,however,seems to be more complex than that
found for OCD. Stein
124 found that while patients with
sexual obsessions had a strong response to SRIs,those
with paraphilias had a more moderate response and
those with PRD had a positive response on low doses,
but a worsening of symptoms on high doses.Open-label
trials of fluoxetine
125 and sertraline
126 found behavioral
improvement in men with paraphilias and in men withPRDs. Sertraline was also found helpful in reducing
pedophiliac fantasy in an open-label trial.
127A retrospec-
tive study of SSRIs found them useful in reducing fan-
tasies in men with paraphilias.
128 Overall, these studies
suggest that,in contrast to OCD,symptom improvement
in SC can be seen in the first few weeks of treatment and
at relatively low doses.Most of these trials were of short
duration,and so response maintenance is unclear;how-
ever,there is indication that response may not be main-
tained in some patients.
126 In addition, compared with
OCD and BDD,case reports indicate that SC may have
a less preferential response to SRIs,also responding to
monotherapy with mood stabilizers
129-131 and non-SRI
antidepressants.
131-133 In terms of SRI dosage, time to
response,response maintenance,and response to other
pharmacotherapies,SC is more like PG,another disorder
characterized by impulsivity,rather than OCD or BDD,
which are more compulsive.One successful augmenta-
tion strategy has been reported.In a case series,Kafka
and Hennen
134 found that men with SC and comorbid
attention deficit-hyperactivity disorder (ADHD)
(assessed retrospectively), who had residual SC symp-
toms despite adequate SSRI treatment, responded to
psychostimulant augmentation.
There has been extensive research into psychological
treatment for several of the paraphilias, such as
pedophilia,due to the severity of the consequences and
the involvement of the justice system.These generally
indicate that CBT programs are relatively effective treat-
ment,though,since they are not 100% effective,there is
a problem with recidivism.
135-137 Few reports of psycho-
logical treatments for SC are available. Following the
addiction model,self-help groups similar to AA are avail-
able,however,their efficacy has not been studied.Case
reports suggest CBT may be effective.
138
Autism spectrum disorders
Individuals with autism spectrum disorders (ASDs),
including autistic disorder,pervasive developmental dis-
order,and Asperger’s disorder,have significant deficits
and/or delays in language and communication, and in
social functioning,and they exhibit significant repetitive
behaviors and restricted interests.
The diagnostic criteria for repetitive behaviors and
restricted interests include ritualistic behaviors,such as
counting,tapping,flicking,or repeatedly restating infor-
mation, and compulsive behaviors, such as lining up
objects,requiring a rigid adherence to routine,a marked
resistance to change,and needing things to be “just so.”
These features are described as obsessive and compul-
sive features of the disorder,
138 marking its similarity to
OCD and the OC spectrum disorders.The ASDs appear
to be on the compulsive,harm-avoidant end of the com-
pulsive-impulsive spectrum.
The lifetime prevalence for all pervasive developmental
disorders,excluding Asperger’s disorder,is 18.7/10 000 in
studies done since 1989;the figure for the full syndrome
of classical autistic disorder is 7.2/10 000.
139There is a large
sex difference in these disorders with males being much
more likely to be affected than are females.The sex ratio
is estimated at 3.1:1 overall for classical autism.
139
Anxiety disorders have been studied in children with high
functioning autism,such as Asperger’s disorder,and results
have shown that anxiety disorders,particularly OCD,are
more prevalent in populations of these children compared
with controls.
140,141The familial aggregation of psychiatric
disorders in the relatives of autistic probands has also been
studied.Bolton et al
142 found the occurrence of OCD was
significantly more common in first-degree relatives of
autistic probands (3%) compared with relatives of Down
syndrome probands (0%).In addition,the authors found
that family members with OCD were also more likely to
exhibit autistic-like social and communication impair-
ments.
142These researchers have also included OCDs as an
indicator of ASD.
142 Piven et al
143 reported a significant rate
of lifetime anxiety disorders in the parents of autistic chil-
dren compared with controls (23.5% versus 2.9%).
Onset of these disorders is believed to be prior to or at
birth,while symptoms are usually not evident until age 2
years or later;generally Asperger’s disorder is not rec-
ognized until later.ASDs are chronic,devastating neu-
ropsychological disorders and are four times more com-
mon in males than females.
While many hypotheses have been explored to explain the
etiology of this cluster of disorders, no single cause has
been agreed upon,though the research exploring genetic
factors is one of the most promising.
144,145 Recent advances
in imaging have been fruitful in research on understand-
ing ASDs.These disorders have very complex and vast
symptoms,but their neural substrates are beginning to be
untangled.At this time,it seems clear that delayed frontal
lobe metabolic maturation occurs in autism,
146 which may
be related to some of the early repetitive behaviors.There
is also bilateral temporal hypoperfusion.
147,148 Overall,there
seems to be a widespread disorganized establishment of
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149Abnormalities in the cerebellum with a
wide range of consequences has also been established.
150
As in OCD,hypotheses of the etiology of ASD suggest
dysregulation of the serotonin system.
151 SRIs,the treat-
ments of choice for OCD,have been used clinically in the
treatment of repetitive behaviors in autism.Promising
results have been found in small controlled trials of the
efficacy of clomipramine and fluvoxamine,
152 and we are
currently conducting controlled studies of the efficacy of
fluoxetine versus placebo in both childhood and adult
autism.
Given the complex,multifaceted symptomatology found
in ASDs, we do not expect one class of agents to be
uniquely effective in treating their global severity.Rather,
it is likely that treatments will be most effective against
targeted symptoms.Since these disorders also have an
impulsive element, with sometimes prominent aggres-
sion,self-injury,and mood instability,we are conducting
a double-blind,placebo-controlled study of the efficacy
of the mood-stabilizer divalproex sodium in children and
adolescents with autism.
Other successful treatments of ASDs include intensive
behavioral therapies are the most widely recognized
modalities of treatment for ASDs. Home- and school-
based behavioral therapies aim toward reducing repeti-
tive and self-/other injurious behaviors and increasing
communication and social skills.
Conclusions
The concept of an OC spectrum of related disorders is
a powerful one that has helped generate theoretical dis-
cussion and research questions in broad areas of their
etiology, neurobiology, and treatment.Though coming
from a wide range of diagnostic categories and differing
in significant ways,research to date suggests that,in addi-
tion to sharing some symptom patterns,these disorders
have many other similarities.OCD has the most devel-
oped knowledge base of these disorders and serves as a
guide for future research in the others.The significant
amount of empirically based knowledge available in
OCD has been valuable in providing direction for both
pharmacological and psychological treatment research,
and is proving important in areas where research is just
beginning,such as neuroimaging.
It is clear that the OC spectrum disorders differ in sys-
tematic ways and that looking at them in terms of com-
pulsivity and impulsivity is adding focus to research on
their etiology,neurobiology,and treatment.Most notably,
research available to date indicates that,while many of
these disorders seem to respond meaningfully to SRI
treatment, the compulsive disorders seem to require
higher dosages,have a substantial latency to response,
and that response is maintained throughout treatment;
in contrast,impulsive disorders may require lower doses
and have a relatively quick response.As research into the
etiology and neurobiology continues,both the concept of
the OC spectrum and the significance of compulsivity
and impulsivity will be tested further. ❏ 
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